Udvalget for Humanmedicinske Lægemidler (CHMP) besluttede, at fordelene ved Glustin er større end risiciene ved behandling af type 2 - diabetes.
The Committee for Medicinal products for Human Use (CHMP) decided that Glustin’ s benefits are greater than its risks for the treatment of type 2 diabetes.